Stay updated with breaking news from Patrick Wingrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/5DHA7FK4SRKA7K4CSVPZCIDJQ4.jpg)
Swiss drugmaker Sandoz said on Saturday it had launched a biosimilar version of AbbVie Inc's big selling arthritis treatment Humira, adding to U.S. competition for the drug that started in January.
Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis drug Humira, while another drugmaker entered...
(Reuters) - Swiss drugmaker Sandoz said on Saturday it had launched a biosimilar version of AbbVie Inc's big selling arthritis treatment Humira, addin...
By Patrick Wingrove (Reuters) - Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version ...
At least four drugmakers are expected to launch new copycat versions of AbbVie's top-selling rheumatoid arthritis drug, Humira, over the next week, but experts expect little change in prices for the treatment even with the new competition. Drugmakers Boehringer Ingelheim, Sandoz and Organon are expected to launch their biosimilars on Saturday, adding to U.S. competition for the drug that started when Amgen released its copy in January. Usually prices fall, often dramatically, when multiple generic versions of a widely used medication enter market.